Diabetes Education News

Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of an automated insulin delivery system compared with standard care, according to findings from a new trial.

Use of AI in medicine is growing quickly. Clinicians are eager to learn what the technology can do, and speakers at meetings across specialties are envisioning its effects — good and bad — in practice management and patient care.

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical organizations to speak out about safety concerns.

Data from the Barbara Davis Center for Diabetes at University of Colorado show pilots with type 1 diabetes are not just thriving in the air, but also with their diabetes management.

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and phentermine/topiramate, but their estimated net price is too high for them to be cost-effective, researchers reported.

Adults with type 1 diabetes who initiated treatment with a bionic pancreas at a primary care site experienced similar glycemic benefits as those starting the device through an endocrinologist, researchers reported.

Testosterone therapy plus lifestyle intervention was tied to a larger improvement in sexual desire than lifestyle intervention alone among older men with impaired glucose tolerance, according to a secondary analysis of the T4DM trial.

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost 15.7% of their body weight at 68 weeks, according to topline data from the REDEFINE 2 trial.

Diabetes mortality declined in the U.S. by 32.1% from 2000 to 2019, with decreases in mortality observed among all racial and ethnic groups and in most U.S. counties, researchers reported in Diabetes Care.